Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach.
Soto R, Perez-Herran E, Rodriguez B, Duma BM, Cacho-Izquierdo M, Mendoza-Losana A, Lelievre J, Aguirre DB, Ballell L, Cox LR, Alderwick LJ, Besra GS. Soto R, et al. Among authors: aguirre db. Sci Rep. 2018 Aug 23;8(1):12664. doi: 10.1038/s41598-018-31157-3. Sci Rep. 2018. PMID: 30140040 Free PMC article.
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Balabon O, Pitta E, Rogacki MK, Meiler E, Casanueva R, Guijarro L, Huss S, Lopez-Roman EM, Santos-Villarejo Á, Augustyns K, Ballell L, Aguirre DB, Bates RH, Cunningham F, Cacho M, Van der Veken P. Balabon O, et al. Among authors: aguirre db. J Med Chem. 2020 May 28;63(10):5367-5386. doi: 10.1021/acs.jmedchem.0c00107. Epub 2020 May 13. J Med Chem. 2020. PMID: 32342688
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Diacon AH, Barry CE 3rd, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh GCKW, Kontsevaya I, Heyckendorf J, Lange C, Reimann M, Penman SL, Scott R, Maher-Edwards G, Tiberi S, Vlasakakis G, Upton CM, Aguirre DB. Diacon AH, et al. Among authors: aguirre db. Nat Med. 2024 Mar;30(3):896-904. doi: 10.1038/s41591-024-02829-7. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365949 Free PMC article. Clinical Trial.
A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
Wozniak A, García P, Geoffroy EA, Aguirre DB, González SA, Sarno VA, Dale JB, Salazar-Echegarai FJ, Vera A, Bueno SM, Kalergis AM. Wozniak A, et al. Among authors: aguirre db. Clin Vaccine Immunol. 2014 Sep;21(9):1343-9. doi: 10.1128/CVI.00330-14. Epub 2014 Jul 23. Clin Vaccine Immunol. 2014. PMID: 25056362 Free PMC article.